Skip to main content
Close

Vancouver Island Centre

If you are interested in more information about a particular trial, please talk with your treating physician first, and they may contact this centre for further information if necessary.

TUMOUR GROUP/SITE TRIAL SUMMARY OPENING DATE
BREASTThis study is being done because women with large breasts have higher rates of skin breakdown (called 'moist desquamation') and breast pain during and shortly after radiation therapy is complete. It is unclear if such skin reactions and pain would be improved by alternating treatment position - namely lying on your belly ("prone") during radiation treatment. (PRONE)Oct 2015
A prospective cohort study evaluating risk of local recurrence following breast conserving surgery and endocrine therapy in low risk Luminal A breast cancer
(LUMINA)
Apr 2013
CENTRAL NERVOUS SYSTEM (CNS)
GASTROINTESTINAL (GI)   
GENITOURINARY (GU) - ProstateA randomised, double-blind, placebo-controlled Phase 3 study of Apalutamide in subjects with high-risk, localized or locally advanced prostate cancer receiving treatment with primary radiation therapy. (ATLAS)Dec 2016

This study will examine the use of stereotactic ablative radiotherapy, in which patients are given only a few, high dose radiation treatments. Treatments are short, non-invasive, applicable to patients not able to do brachytherapy, and may be more effective than conventional external beam radiation therapy. (ASSERT)Apr 2016
Investigating the immune response to prostate cancer in subjects undergoing standard treatment
(*Deeley Research Centre)
2005
GENITOURINARY (GU) - Kidney
  
GENITOURINARY (GU) - Bladder
 
GYNE - Ovary IROC - The Immune Response to Ovarian Cancer
(*Deeley Research Centre)
Aug 2007
HEAD AND NECK
LUNG 

LYMPHOMAIROL - The Immune Response to Lymphoma
(*Deeley Research Centre)
 
MELANOMA
SARCOMA  
SUPPORTIVE / PALLIATIVE CARE  
SYMPTOM MANAGMENT
 
MULTI SITEA non-randomized phase II trial where all participants will receive experimental Stereotactic Ablative Radiotherapy (SABR) to all sites of progressing metastatic disease
(SABR-5/SABR for Oligimetastases)

Jan 2017

Personal REsponse Determinants in Cancer Therapy - (PREDICT) Jan 2006
SOURCE: Vancouver Island Centre ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer Agency. All Rights Reserved.

    Copyright © 2017 Provincial Health Services Authority